Results 141 to 150 of about 3,987 (159)

<p>New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic</p>

Biologics: Targets and Therapy, 2019
Marco Caminati, Rachele Vaia, Diego Bagnasco   +2 more
exaly  

Aminophylline/benralizumab

Reactions Weekly, 2023
openaire   +1 more source

Benralizumab/vedolizumab

Reactions Weekly, 2023
openaire   +1 more source

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

Expert Opinion on Biological Therapy, 2012
William J Calhoun
exaly  

Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review

International Journal of Molecular Sciences, 2020
Koichi Ando, Hironori Sagara, Akihiko Tanaka   +2 more
exaly  

Benralizumab/ciclosporin

Reactions Weekly, 2021
openaire   +1 more source

Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma

Expert Opinion on Drug Metabolism and Toxicology, 2017
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola   +2 more
exaly  

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

Lancet, The, 2016
Parameswaran Nair, Eugene Bleecker, J Mark Fitzgerald   +2 more
exaly  

Benralizumab

Reactions Weekly, 2019
openaire   +1 more source

Benralizumab: An anti-IL-5 Receptor α Monoclonal Antibody in the Treatment of Asthma

Immunotherapy, 2018
Maciej Kupczyk, Piotr Kuna
exaly